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Summary  Many  epidemiological  studies  have  demonstrated  that  resting  heart  rate  is  a  risk
marker but  also  a  risk  factor  in  patients  with  coronary  artery  disease  and  heart  failure.  In
hypertensive  subjects  free  from  overt  cardiac  disease,  the  question  has  been  less  frequently
addressed.  A  few  cohort  studies  have  shown  that  hypertensive  patients  with  a  high  resting
heart rate  have  an  increased  risk  of  all-cause  and  cardiovascular  death.  However,  intervention
trials have  not  demonstrated  that  lowering  the  heart  rate  is  beneﬁcial  in  hypertensive  subjects.
Studies with  an  assessment  of  ambulatory  heart  rate  tend  to  demonstrate  a  better  association
between cardiovascular  outcomes  and  variables,  including  nighttime  heart  rate.  Clinical  trials
comparing  beta-blockers  with  non-slowing  antihypertensive  drugs  have  not  demonstrated  the
superiority  of  the  former.  Finally,  an  elevated  resting  heart  rate  in  hypertensive  subjects  free
from overt  cardiac  disease  seems  to  be  more  a  risk  marker  than  a  risk  factor.  Although  these
patients  are  at  high  risk,  no  scientiﬁc  data  exist  to  support  targeting  heart  rate.  In  this  review,
we describe  the  pathophysiological  effects  of  heart  rate,  including  vascular  cell  signalling,  link
with sympathetic  activity  and  inﬂuence  on  central  blood  pressure,  and  the  prognostic  value  and
management  of  HR  in  hypertensive  patients  free  from  overt  cardiac  diseases.
© 2013  Elsevier  Masson  SAS.  All  rights  reserved.
Abbreviations: ACE, angiotensin-converting enzyme; BP, blood pressure; bpm, beats per minute; ECG, electrocardiogram; HR, heart
ate; PWV, pulse wave velocity.
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Résumé  De  nombreuses  études  épidémiologiques  ont  démontré  qu’une  fréquence  cardiaque
de repos  élevée  était  un  marqueur  de  risque  mais  également  un  facteur  de  risque  cardio-
vasculaire  chez  les  patients  coronariens  et  insufﬁsants  cardiaques.  À  l’inverse,  les  données
scientiﬁques  sont  bien  plus  faibles  concernant  la  fréquence  cardiaque  chez  le  patient  hyper-
tendu ne  présentant  pas  de  pathologie  cardiaque  associée.  Dans  cette  revue  de  la  littérature,
nous décrivons  le  rôle  physiopathologique  de  la  fréquence  cardiaque  (effet  sur  la  cellule  vascu-
laire, lien  avec  le  tonus  sympathique  et  inﬂuence  sur  la  pression  artérielle  centrale).  Quelques
études de  cohorte  ont  permis  de  démontrer  qu’une  fréquence  cardiaque  de  repos  élevée  était
associée à  une  mortalité  toute  cause  et  cardiovasculaire  accrue.  Les  études  pour  lesquelles  des
données concernant  la  mesure  ambulatoire  de  la  fréquence  cardiaque  sont  disponibles  tendent  à
démontrer que  le  pronostic  cardiovasculaire  est  lié  essentiellement  aux  paramètres  nocturnes.
Les études  ayant  comparé  dans  l’hypertension  artérielle  les  anti-hypertenseurs  non  bradycardis-
ant aux  béta-bloquants  n’ont  jamais  démontré  la  supériorité  de  ces  derniers.  En  conclusion,
une fréquence  cardiaque  élevée  chez  un  patient  hypertendu  sans  cardiopathie  avancée  semble
être davantage  un  marqueur  de  risque  qu’un  facteur  de  risque  cardiovasculaire.  Bien  que  ces
patients soient  à  haut  risque,  nous  n’avons  pour  l’instant  pas  un  niveau  de  preuve  sufﬁsant  pour
faire de  la  fréquence  cardiaque  une  cible  thérapeutique.
© 2013  Elsevier  Masson  SAS.  Tous  droits  réservés.
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Human  and  animal  studies  have  demonstrated  a  prospec-
tive  association  between  increased  HR  and  the  incidence  ofBackground
Heart  rate  (HR)  is  of  prognostic  value  in  the  general  pop-
ulation  [1—5]  and  in  patients  with  coronary  artery  disease
[6—8]  or  chronic  heart  failure  [9—11].  Regarding  coronary
artery  disease,  we  have  convincing  evidence  to  support  con-
sidering  HR  as  a  risk  factor.  First,  a  direct  link  between
high  HR  and  the  formation  of  atherosclerotic  lesions  has
been  proved  in  animals  [12—14].  Moreover,  in  humans,  an
increased  HR  induced  by  atrial  pacing  increased  diameter
and  blood  ﬂow  in  angiographically  normal  coronary  arter-
ies,  while  it  induced  a  paradoxical  narrowing  in  patients
with  advanced  obstructive  atherosclerosis  [15].  Therefore,
the  haemodynamic  forces  associated  with  a  resting  HR  >  80
beats  per  minute  (bpm)  may  also  play  a  crucial  role  in  the
pathogenesis  of  coronary  plaque  disruption  in  humans  [16].
Epidemiological  data  have  conﬁrmed  that  patients  with  a
resting  HR  ≥  83  bpm  have  a  signiﬁcantly  higher  risk  of  car-
diovascular  death  [7,17,18].  Finally,  the  reduction  of  HR
in  beta-blocker  or  ivabradine  trials  concerning  coronary
artery  diseases  was  correlated  with  a  decrease  in  mortality
[19,20].
Similar  pathophysiological  links  exist  for  heart  failure.
First,  elevated  HR  is  an  adaptive  compensation  for  reduced
cardiac  output  [21].  The  associated  hyperadrenergic  state
leads  to  myocardial  ischaemia  as  a  consequence  of  increased
myocardial  oxygen  consumption  and  shortening  of  the  dias-
tole  [22].  Intervention  trials  performed  in  the  setting  of
heart  failure  also  demonstrated  that  cardiac-slowing  drugs
reduce  cardiovascular  death  [9,10].  The  recent  European
guidelines  on  heart  failure  recommend  a  target  HR  of  70  bpm
[23].
In  hypertension,  the  situation  has  been  less  frequently
addressed.  This  review  focuses  on  current  pathophysiologi-
cal  concepts  and  the  prognostic  value  and  management  of
HR  in  hypertensive  patients  free  from  overt  cardiac  dis-
eases.
o
rathophysiological effects of heart rate
n  elevated  HR  can  be  deleterious  in  different  ways  in  hyper-
ensive  patients.  We  will  brieﬂy  describe  what  is  known
bout  the  cellular,  sympathetic,  biomechanical  and  clinical
spects  of  this  topic.
ascular cell signalling
n  vitro  studies  have  demonstrated  that  an  increase  in  pul-
atile  frequency  (a  similar  mechanical  effect  to  elevated
R)  on  vascular  endothelial  cells  induces  a  proinﬂammatory
henotype  [24],  an  increase  in  procoagulant  transcript  [25]
nd  the  formation  of  reactive  oxygen  species  (Fig.  1)  [26].
he  effects  of  elevated  HR  are  also  numerous  on  vascular
mooth  muscle  cells—namely,  upregulation  of  extracellular
atrix  protein  (ﬁbronectin,  collagen)  [27,28],  growth  fac-
ors  [29]  and  osteogenic  markers  [30]  and  ampliﬁcation  of
xidative  stress  [31]. All  these  data  suppose  that  chronic
xposure  to  elevated  HR  can  lead  to  earlier  atherosclerotic
esion  development  and  the  progression  of  arterial  stiffness.
ink between heart rate and sympathetic
ctivity
he  sinoatrial  node  is  under  the  control  of  physical  and  men-
al  activity,  through  the  autonomic  system  and  circulating
ormones.  Therefore,  increased  HR  can  reﬂect  an  imbalance
etween  increased  sympathetic  tone  and  decreased  vagal
one.  Resting  HR  is  known  as  an  indicator  of  poor  physical
ealth  or  low  physical  activity,  related  to  downregulation  of
arasympathetic  tone,  which  can  be  improved  by  increasing
hysical  exercise  [32,33].besity  [34,35]  or  metabolic  abnormalities—namely,  insulin
esistance  [36,37]. Norepinephrine  is  the  main  hormone
50  P.-Y.  Courand,  P.  Lantelme
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sigure 1. Vascular cell signalling.
eleased  by  the  adrenal  gland  in  response  to  sympa-
hetic  tone.  Plasma  norepinephrine  concentrations  have
een  shown  to  predict  future  blood  pressure  (BP)  elevation
nd  weight  gain  in  lean  normotensives  [38]. Long-standing
xposure  to  sympathetic  overactivity  induces  the  downregu-
ation  of  adrenoreceptor-mediated  thermogenic  responses.
n  impairment  to  this  mechanism  may  be  important  in  pro-
oting  and  maintaining  excess  body  weight  [39].
nﬂuence of heart rate on central pressure
he  Conduit  Artery  Function  Evaluation  (CAFE)  study  [40,41]
nd  another  cross-sectional  study  [42]  have  demonstrated
he  inﬂuence  of  HR  on  augmentation  index.  A  lower  HR
as  associated  with  higher  aortic  systolic  pressure  and  pulse
ressure;  this  observation  was  attributed  to  increased  cen-
ral  pressure  wave  reﬂections  at  lower  HR,  as  illustrated
n  Fig.  2.  The  increase  in  systolic  central  pressure  seems
ttributable  to  a  shift  of  the  reﬂected  wave  into  late  sys-
ole,  secondary  to  the  reduction  in  ejection  duration  by
R  lowering,  and  an  increased  stroke  volume,  secondary
o  HR  reduction  (longer  diastolic  time).  Of  note,  two  other
ajor  components  also  modulate  central  pressure:  pulse
ave  velocity  (PWV)  and  peripheral  arterial  resistance  [44].
n  increase  in  both  of  these  components  induces  an  earlier
ackward-reﬂected  wave  and,  as  a  consequence,  a higher
entral  systolic  BP.
nﬂuence of heart rate on incidence of
ypertension and target organ damage
wo  longitudinal  studies  have  demonstrated  that  an  ele-
ated  HR  at  baseline  increases  the  risk  of  developing
ypertension:  there  was  a  60%  higher  risk  in  a  Japanese
ohort  for  the  highest  quartile  [45]  and  a  doubled
isk  in  patients  with  HR  >  85  bpm  in  the  HARVEST  study
46].
Our  team  has  previously  demonstrated  that  increasing
he  HR  sharply  by  pacing  leads  to  an  increased  PWV  [47].
his  hypothesis  was  supported  in  a  6-year  longitudinal  study:
I
v
w
dncreased  HR  was  one  of  the  most  powerful  predictors  of
ccelerated  progression  of  arterial  stiffness  [48]. Two  others
tudies  have  also  demonstrated  this  longitudinal  relation-
hip  between  HR  and  PWV  [49,50].  An  increase  in  PWV  can
ncrease  the  central  BP  by  inducing  a  shorter  reﬂected  pres-
ure  wave  return  time.  In  a  large  population  of  high-risk
ypertensive  patients,  elevated  HR  was  also  an  indepen-
ent  predictor  of  the  development  of  microalbuminuria
51].
rognostic value of heart rate in
ypertension
rognostic value of  resting heart rate
n  hypertensive  patients  without  overt  cardiovascular  dis-
ase,  six  cohort  studies  have  tested  the  relationship
etween  resting  HR  and  mortality;  the  studies  had  very  dif-
erent  follow-up  periods,  ranging  from  2  to  36  years  (Table  1)
1,52—56]. Overall,  ﬁve  of  the  studies  [1,52—55]  conﬁrmed
 strong  association  between  high  HR  and  all-cause  mortality
fter  adjustment  for  classical  risk  factors.  Benetos  et  al.  [1]
eported  a  non-signiﬁcant  association  with  all-cause  mortal-
ty  in  women,  a  result  that  was  not  conﬁrmed  in  other  studies
52,54].  While  the  mean  age  of  the  cohorts  ranged  from
5  to  70  years  and  the  methods  of  HR  measurement  varied
electrocardiogram  [ECG],  pulse  palpation),  the  association
emained  statistically  signiﬁcant.
The  association  between  elevated  HR  and  cardiovascu-
ar  mortality  seems  weaker  but  has  also  been  demonstrated
n  ﬁve  studies  [1,52—54,56]. Thomas  et  al.  showed  that
his  relationship  was  of  similar  magnitude  in  young  and  old
ypertensive  subjects  [56]. We  recently  demonstrated  that
ortic  atherosclerosis  and  overt  cardiac  disease  are  strong
ffect  modiﬁers  of  the  prognostic  value  of  HR;  both  increase
trongly  the  hazard  ratio  for  cardiovascular  mortality  [52].
n  the  Glasgow  Blood  Pressure  Clinic  Study,  a  persistent  ele-
ated  HR  after  different  follow-up  physical  examinations
as  associated  with  an  increased  risk  of  all-cause  and  car-
iovascular  mortality  [55].
Signiﬁcance,  prognostic  value  and  management  of  heart  rate  in  
Figure 2. Modiﬁcation of central pressure in response to heart
rate reduction. Heart rate reduction increases central systolic blood
pressure (SBP) for the same pulse height of the forward-ejected
pressure wave and the same reﬂected pressure wave. T0: onset
of the forward-ejected wave; T1: time for the backward-reﬂected
wave to return to the aorta from T0; T2: end of the ejection dura-
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Adapted from Safar et al. [43].
Two  clinical  trials,  designed  primarily  to  compare
different  antihypertensive  strategies,  also  analysed  the
prognostic  value  of  HR  in  hypertensive  patients  free  from
overt  cardiac  disease  (Table  1).  In  the  LIFE  study,  hyperten-
sive  patients  all  had  ECG  left  ventricular  hypertrophy  and
were  treated  with  losartan-  and  atenolol-based  regimens
[57].  A  10-bpm  higher  resting  HR  was  associated  with  a  25%
increased  risk  of  cardiovascular  or  all-cause  mortality.  More-
over,  the  persistence  or  the  development  of  an  HR  ≥  84  bpm
A
p
mhypertension  51
uring  the  follow-up  period  doubled  cardiovascular  and  all-
ause  death.  Finally,  in  the  VALUE  study  (a  comparison  of
alsartan  and  amlodipine  regimens),  baseline  and  follow-up
Rs  >  79  bpm  were  also  predictors  of  cardiovascular  outcome
58]; of  note,  around  50%  of  patients  had  overt  coronary
rtery  disease.
rognostic value of home resting heart rate
hile  home  BP  is  of  particular  interest,  only  one  study  has
een  performed  to  test  the  prognostic  value  of  home  resting
R  in  the  general  population.  In  a  cohort  that  included  1780
apanese  subjects,  home  HR  was  a  signiﬁcant  predictor  of
ardiovascular  mortality  [59].
rognostic value of ambulatory heart rate
even  studies  have  tested  the  prognostic  value  of  ambula-
ory  HR  obtained  during  ambulatory  BP  measurement  (at
east  10  readings  during  24  hours)  in  hypertensive  subjects
Table  2).  Hansen  et  al.  [62]  demonstrated  that  24-hour  HR
nd  daytime  HR  have  strong  prognostic  value  in  predicting
ll-cause  and  non-cardiovascular  mortality.  The  only  vari-
ble  that  predicted  cardiovascular  mortality  was  the  night:
ay  HR  ratio.  A  recent  analysis  showed  that  nighttime  HR
as  a  better  predictor  of  cardiovascular  events  than  day-
ime  HR  [63].  Verdecchia  et  al.  demonstrated  that,  after
djustment  for  BP  and  other  risk  factors,  each  10%  decrease
n  the  nocturnal  slowing  of  HR  was  associated  with  higher
otal  mortality  (hazard  ratio  1.30;  95%  CI  1.02—1.65)  but
ot  with  cardiovascular  events  [60].  Ben-Dov  et  al.  demon-
trated  quite  similar  results:  total  mortality  increased  with
 higher  sleeping  HR  (P  =  0.02)  and  decreased  with  a  greater
octurnal  fall  in  HR  (P  <  0.001)  but  was  unrelated  to  HR  when
wake  (P  =  0.50)  [61].
In contrast,  in  a subgroup  analysis  of  Syst-Eur  [54],  ambu-
atory  HR  was  recorded  during  the  run-in  period  in  807
ntreated  patients:  none  of  the  ambulatory  HR  measure-
ents  predicted  non-fatal  events  or  non-fatal  combined
ith  fatal  endpoints,  respectively.  Two  other  population
tudies  also  failed  to  detect  any  association  between  car-
iovascular  mortality  and  24-hour,  daytime  or  nighttime  HR
65].
Taken  as  a  whole,  these  studies  tend  to  demonstrate
 better  association  between  cardiovascular  outcomes  and
ariables,  including  nighttime  HR.  Some  explanations  have
een  advanced:  HR  during  sleep  is  more  stable  than  HR  dur-
ng  waking  hours,  which  is  inﬂuenced  by  physical  activities
r  emotional  triggers  [63]. Moreover,  an  elevated  sleeping
R  can  also  represent  persistent  sympathetic  overactivity
nd  is  a  better  reﬂection  of  the  mechanical  stress  on  the
rterial  wall.
linical implication of elevated heart rate
n  hypertension
easurement of heart rate working  group  from  the  European  Society  of  Hypertension
ublished  a European  consensus  recommendation  in  2006  to
easure  resting  HR  [64]: the  patient  should  be  allowed  to  sit
52
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Table  1  Cohorts  demonstrating  the  impact  of  heart  rate  on  mortality  in  hypertensive  subjects.
Study  Year  n  Mean  age  (years)  Heart  rate
measurement
Follow-up  (years)  Hazard  ratio  [conﬁdence  interval]a
All-cause  mortality  Cardiovascular  mortality
Gillmann  [53]  1993  2037  men  55  ECG  (+40  bpm)  36  1.98  [1.52—2.59]  1.48  [1.05—2.09]
2493  women  57  ECG  (+40  bpm)  1.87  [1.37—2.56]  1.37  [0.85—2.21]
Benetos  [1]  1999  12,123  men  51  ECG  (+20  bpm)  18  P  <  0.001b P  <  0.05b
7263  women  52  ECG  (+20  bpm)  NSb NSb
Thomas  [56]  2001  64,912  men  <  55  years  37  ECG  (≤  80  vs
>  80  bpm)
14 —  1.48  [1.22—1.78]
15,281  men  ≥  55  years  59  ECG  (≤  80  vs
>  80  bpm)
— 1.32  [1.11—1.56]
Palatini  [54]  2002  2293  men  and  women  70  Pulse
palpation
(≤  79  vs
> 79  bpm)
2 1.94  [1.33—2.84]  1.60  [0.99—2.29]
Paul  [55]  2010  4065  men  and  women  52  Pulse
palpation
(HR  ≥  5  vs
≤  0  bpm)
2.5  1.51  [1.03—2.20]  1.46  [0.99—2.13]
LIFE  [57]  2010  9190  men  and  women  67  ECG  (+10  bpm)  6  1.25  [1.17—1.33]  1.16  [1.06—1.27]
ECG  (≤  84  vs
>  84  bpm)
1.79  [1.46—2.21]  1.55  [1.16—2.05]
VALUE  [58] 2012  15,193  men  and  women  67  ECG  (+10  bpm)  5  1.19  [1.15—1.23]  1.16  [1.12—1.20]
Courand  [52]  2013  1204  men  and  women  45  Pulse
palpation
(+10  bpm)
35 1.12  [1.06—1.19]  1.10  [1.02—1.20]
Pulse
palpation
(≤  82  vs
> 82  bpm)
1.39  [1.18—1.64]  1.37  [1.09—1.72]
bpm: beats per minute; ECG: electrocardiogram; HR: heart rate; NS: not signiﬁcant.
a Hazard ratio and conﬁdence intervals for all-cause and cardiovascular mortality are adjusted for all risk factors.
b Hazard ratio and conﬁdence intervals not provided.
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Table  2 Studies  demonstrating  the  impact  of  ambulatory  heart  rate  on  cardiovascular  events  in  hypertensive  subjects.
Study  Year n Age  (years) Heart  rate  measurement Follow-up  (years) Hazard  ratio  [conﬁdence  interval]a
All-cause  mortality Cardiovascular  mortality
Palatini  [54] 2002  807  70  24-hour  ABPM 2  1.54  [0.76—3.12] 0.68  [0.22—2.11]
Daytime-ABPM  1.27  [0.60—2.65] 0.32  [0.07—1.41]
Nighttime-ABPM  1.59  [0.77—3.30] 0.71  [0.22—2.29]
(+10  bpm)
Verdecchia  [60] 1998  1942  52  24-hour  ABPM 10  NSb —
Daytime-ABPM  NSb —
Nighttime-ABPM  NSb —
Ben-Dov  [61]  2007  3957  55  Heart  dipping  lowest  vs  highest  decile  14  2.67  [1.31—5.47]  —
Hansen  [62] 2008  6928  56  24-hour  ABPM  15  1.15  [1.06—1.25]  1.11  [0.97—1.26]
Daytime-ABPM  1.08  [0.99—1.16] 1.05  [0.92—1.19]
Nighttime-ABPM  1.20  [1.11—1.30] 1.15  [1.01—1.31]
(+10  bpm)
Palatini  [63] 2013  7600  52  24-hour  ABPM  5  —  1.11  [1.00—1.20]
Daytime-ABPM  —  1.08  [0.99—1.18]
Nighttime-ABPM  —  1.13  [1.04—1.22]
(+10  bpm)
Sega  [64]  2005  2051  50  24-hour  ABPM  10  NSb NSb
Daytime-ABPM  NSb NSb
Nighttime-ABPM  NSb NSb
ABPM: ambulatory blood pressure monitoring; NS: not signiﬁcant.
a Hazard ratio and conﬁdence intervals for all-cause and cardiovascular mortality are adjusted for all risk factors.
b Hazard ratio and conﬁdence intervals not provided.
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or  at  least  5  minutes  in  a  quiet  room  at  a  comfortable  tem-
erature;  HR  should  be  measured  over  a  30-second  period
y  pulse  palpation;  at  least  two  measurements  should  be
aken  in  the  sitting  position;  in  subjects  in  whom  orthostatic
P  measurement  is  performed,  HR  should  be  measured  after
ach  BP  reading;  and  patients  measuring  their  own  BP  should
lso  collect  HR  data.
Ambulatory  HR  should  also  be  available  frequently  from
ost  hypertensive  patients,  as  the  recent  French  guidelines
ecommend  ambulatory  BP  measurement  in  all  patients  with
fﬁce  grade  1  or  2  hypertension  before  starting  antihyper-
ensive  treatment  [66].
iagnostic implication of elevated heart rate
lthough  it  seems  difﬁcult  to  deﬁne  a  threshold  for  an
bnormal  resting  elevated  HR,  it  is  reasonable  to  suppose
hat  a  resting  HR  >  80—85  bpm  should  alert  clinicians  [64].
he  ﬁrst  step  must  rule  out  associated  comorbidity,  such
s  arrhythmias  (e.g.  atrial  ﬁbrillation  and  atrial  ﬂutter),
naemia,  hyperthyroidism  and  sepsis.  In  the  absence  of
vident  causes,  the  physician  must  investigate  mild  symp-
oms  of  heart  failure  or  cardiorespiratory  mismatch.  To
ifferentiate  these  two  diagnoses,  plasma  concentrations
f  natriuretic  peptides  and  transthoracic  echocardiography
impairment  of  diastolic  or  systolic  functions)  can  be  helpful
23].
In  addition,  a  high  sleeping  HR  obtained  via  ambulatory
P  measurement  may  reﬂect  episodes  of  sleep  apnoea  that
re  associated  with  an  increase  in  sympathetic  drive.  Par-
icularly  in  the  presence  of  resistant  hypertension  with  a
on-dipping  HR  proﬁle,  physicians  must  look  for  symptoms
f  sleep  apnoea  and,  if  useful,  perform  a  polysomnography
67].
herapeutic management of elevated heart
ate
lthough  an  increased  HR  has  been  recently  demonstrated
s  a  long-term  predictor  of  cardiovascular  events  in  patients
ith  high-risk  hypertension,  the  value  of  decreasing  the  HR
aries  according  to  the  clinical  context.  In  the  presence  of
ymptomatic  heart  failure  or  coronary  artery  disease,  HR-
lowing  drugs,  such  as  beta-blockers  or  ivabradine,  are  of
articular  beneﬁt  [23].
Overall,  in  hypertension,  intervention  trials  that  com-
ared  beta-blockers  with  non-slowing  antihypertensive
rugs  (thiazides,  diuretics,  angiotensin-converting  enzyme
ACE]  inhibitors,  angiotensin  receptor  blockers  and  calcium
hannel  blockers)  failed  to  demonstrate  the  superiority  of
he  former  [68—73].  Besides,  the  Anglo-Scandinavian  Car-
iac  Outcomes  Trial  (ASCOT)  demonstrated  that  the  group
iven  beta-blockers  as  ﬁrst-line  treatment  had  a  worse
ardiovascular  outcome  [69],  even  those  patients  with  a
igh  baseline  HR  [72].  Moreover,  in  patients  with  hyperten-
ion,  Bangalore  et  al.  showed  in  a  metaregression  analysis
hat  the  lower  the  HR  obtained  with  beta-blockers,  the
orse  the  prognosis  (i.e.  the  higher  the  risks  of  cardiovas-
ular  events  and  death)  [74].  The  disappointing  effects  of
eta-blockers  in  hypertension  have  been  attributed  to  their
nfavourable  effects  on  lipid  proﬁle  and  insulin  resistance
75].  The  higher  central  BP  with  beta-blocker-based  therapy
a
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ompared  with  a  calcium  entry  blocker/ACE-inhibitor  asso-
iation  found  recently  in  the  CAFE  study  (see  the  section
ntitled  ‘Inﬂuence  of  heart  rate  on  central  pressure’)  is
nother  possible  cause  of  the  lower  effect  of  beta-blockers
n  patients  without  overt  cardiac  disease  [40,41]. The  higher
ystolic  central  pressure  was  attributed  mainly  to  a  shift  of
he  reﬂected  wave  into  late  systole  due  to  the  reduction
n  ejection  duration  at  lower  HR  and  to  the  vasoconstrictor
ffect  of  beta-blockers  (a  pharmacological  property  of  most
eta-blockers,  including  atenolol,  which  was  used  in  this
tudy)  on  the  peripheral  circulation,  which  increases  pulse
ave  reﬂection.  The  novel  nitrovasodilating  beta-blocker
ebivolol  reduces  aortic  pulse  pressure  more  than  atenolol,
hich  may  be  related  to  a less  pronounced  rise  in  the  cen-
ral  augmentation  index  and  bradycardia  [76].  Whether  this
ill  translate  into  differences  in  clinical  outcome  has  yet  to
e  tested.
As  far  as  the  calcium  antagonists  are  concerned,  although
hey  reduce  HR  to  a  lesser  degree  compared  with  beta-
lockers,  they  are  free  of  the  adverse  metabolic  effects,
hich  are  common  to  the  latter.  However,  only  two  studies
ave  compared  diltiazem  with  atenolol:  one  in  hyperten-
ive  patients  free  from  overt  cardiac  disease  [77],  and
nother  in  hypertensives  with  coronary  artery  disease  [78].
hese  studies  did  not  demonstrate  superiority  of  one  agent
ver  the  other.  Recently,  ivabradine  has  been  introduced,
hich  is  a  new  selective  HR-lowering  agent  that  affects  only
he  HR  without  exerting  any  inotropic  or  antihypertensive
ction.  Although  ivabradine  has  promising  antiatheroscle-
otic  properties,  its  efﬁcacy  in  reducing  atherosclerosis  and
elated  clinical  outcomes  needs  to  be  tested  in  hypertensive
atients.
Thus,  in  hypertensive  subjects  without  heart  disease,
owering  HR  does  not  seem  to  confer  additional  advantages.
he  recent  French  guidelines  [66]  have  gone  a  step  further
y  removing  beta-blockers  as  the  cornerstone  of  resistant
ypertension,  with  the  result  that,  in  principle,  HR  can  no
onger  be  lowered  in  most  hypertensive  subjects.  Neverthe-
ess,  in  hypertensive  patients  with  a  resting  HR  >  85  bpm,
R  could  be  lowered  with  a  programme  of  regular  aerobic
xercise.  However,  we  know  about  the  poor  compliance  of
ubjects  with  non-pharmacological  measures.
We  could  hypothesize  that  HR  reﬂects  an  impairment
f  ventricular-arterial  coupling  in  hypertensive  patients.
amage  induced  at  the  level  of  the  heart  or  vessels  lev-
ls  by  long-term  exposition  to  hypertension  is  not  always
eversible.  In  treating  elevated  HR  in  hypertensive  patients,
e  probably  target  only  the  consequence  and  not  the  cause.
oreover,  the  ideal  HR  probably  varies  from  one  patient  to
nother,  particularly  according  to  vessel  and  heart  proper-
ies.
Recently,  a catheter-based  approach  to  denervate  the
idneys  has  been  successfully  introduced  into  clinical  prac-
ice;  it  has  been  shown  to  reduce  BP  and  sympathetic
ctivity  in  patients  with  resistant  hypertension  without
igniﬁcant  systematic  side  effects  [79]. A  recent  study  per-
ormed  in  136  patients  treated  with  renal  sympathetic
enervation  demonstrated  a  marked  decrease  of  9  bpm  in subgroup  of  patients  with  a  resting  HR  >  71  bpm  [80].
he  change  in  resting  HR  can  provide  a  new  criterion  of
esponse  or  non-response  to  renal  sympathetic  denerva-
ion.
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Conclusion
HR  is  a  simple  clinical  index,  which  should  be  used  in
daily  practice  to  assess  the  risk  of  hypertensive  patients.
Many  studies  have  demonstrated  the  increased  risk  associ-
ated  with  an  elevated  HR  >  80  bpm.  However,  in  this  clinical
setting,  we  have  no  scientiﬁc  data  to  support  the  use  of
beta-blockers  as  a  ﬁrst-line  treatment.  In  contrast,  physi-
cians  should  carefully  evaluate  these  patients  to  rule  out
mild  signs  of  heart  failure  or  cardiorespiratory  mismatch.
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